...
首页> 外文期刊>PLOS Neglected Tropical Diseases >Immunogenicity of a killed bivalent whole cell oral cholera vaccine in forcibly displaced Myanmar nationals in Cox's Bazar, Bangladesh
【24h】

Immunogenicity of a killed bivalent whole cell oral cholera vaccine in forcibly displaced Myanmar nationals in Cox's Bazar, Bangladesh

机译:在Cox的Bazar,Bangladesh的强行流离失所者国民杀死二价全细胞口腔胆汁疫苗的免疫原性

获取原文
           

摘要

Oral cholera vaccines (OCV) are now on the WHO stockpile and targeted for use for countries with outbreaks and epidemics but also for control of endemic cholera. In Bangladesh many studies have been carried out to assess the safety, immunogenicity as well as feasibility of vaccination in the endemic settings of the country. However, with the large recent influx of displaced Rohingya nationals from Myanmar (termed Forcibly Displace Myanmar National; FDMN), mass campaigns with OCV were conducted between October 2017-December 2018. However, no data is available of the previous exposure to cholera of this population, prior to their arrival in Bangladesh. An assessment of immunogenicity status of FDMN is needed to find out if OCV is able to elicit comparable immune response and whether the same dose regimen of OCV was immunogenic among the FDMNs. In this study, we have measured the immune responses to the OCV, Shanchol, in adults (18 years and above), older children (6 17 years), and younger children (1 5 years). The results of this study shows that the oral cholera vaccine capable of inducing an immune response in adults and children among this FDMN population and the responses were comparable to that seen in Bangladeshi participants in earlier studies.
机译:口腔霍乱疫苗(OCV)现在正在储存的世界卫生组织和针对具有爆发和流行病的国家,而且还用于控制流行霍乱。在孟加拉国,已经进行了许多研究,以评估该国的地方性环境中疫苗接种的安全性,免疫原性以及可行性。然而,随着来自缅甸的大量流离失所者洛藏国民涌入(被强行取代缅甸国家; FDMN),与OCV的大规模运动在2017年10月至2018年10月之间进行。但是,没有任何数据可以获得以前的霍乱暴露于此人口,在抵达孟加拉国之前。需要评估FDMN的免疫原性状态,以发现OCV是否能够引发可比性免疫应答,并且在FDMNS中是否具有相同的OCV剂量方案是免疫原性。在这项研究中,我们测量了对ICV,Shanchol,成人(18岁及以上),年龄较大的儿童(617岁)和年轻儿童(1 5年)的免疫反应。该研究的结果表明,能够在此FDMN群体中诱导成人和儿童免疫应答的口腔霍乱疫苗以及孟加拉国参与者在早期研究中的答复相当。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号